UNSPSC 51372003: Buprenorphine

This classification denotes an opioid receptor agonist and opioid with the molecular formula C29H41NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 40D3SCR4GZ, chemically known as 6,14-ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, (5-alpha,7-alpha-(s))- but generally known as buprenorphine, which bears US NIH Compound Identifier 40400. Buprenorphine most often comes in base and hydrochloride forms.

UNSPSC 51372003 Buprenorphine is a Commodity code for prescription opioid-use-disorder medications procured primarily through state health agencies and county health departments. State and local procurement activity under this code centers on bulk pharmaceutical supply agreements, often as part of larger addiction-treatment and harm-reduction initiatives funded through state health budgets or federal pass-through funding. The issuing bodies are predominantly state health and human services departments and county public-health divisions; Seminole County, Florida and the Texas Health and Human Services Commission appear in current-year activity. The work solicited ranges from direct supply agreements with manufacturers to cooperative purchasing arrangements that aggregate demand across multiple state and local entities and their authorized wholesale distributors.

Recent opportunities reflect two distinct purchasing models. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking annual supply of naloxone and drug-deactivation systems with quarterly deliveries to the Seminole County Community Health Building in Sanford, an intake-control procurement with a two-year term and one-year renewal option, fixed-fee pricing, and E-Verify and drug-free workplace compliance required. The Texas Health and Human Services Commission released RFI HHS0017013 in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and wholesale channels, signaling exploratory procurement before formal solicitation. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 proposal deadline, requiring vendors to supply through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) with pricing weighted at 75 percent of evaluation and a July 1, 2026 contract effective date. Geographic activity spans Florida, Texas, and Minnesota with multi-state reach through cooperative vehicles.